Poseida Historical Balance Sheet

PSTX Stock

USD 9.31 0.02 0.21%

Trend analysis of Poseida Therapeutics balance sheet accounts such as Accounts Payable of 3.5 M, Other Assets of 1.2 M, Net Receivables of 5.2 M or Other Stockholder Equity of 732.7 M provides information on Poseida Therapeutics' total assets, liabilities, and equity, which is the actual value of Poseida Therapeutics to its prevalent stockholders. By breaking down trends over time using Poseida Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Poseida Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Poseida Therapeutics is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Poseida Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.

About Poseida Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Poseida Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Poseida Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Poseida Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Poseida currently owns. An asset can also be divided into two categories, current and non-current.

Poseida Therapeutics Balance Sheet Chart

At this time, Poseida Therapeutics' Net Working Capital is fairly stable compared to the past year. Short Term Debt is likely to rise to about 8.1 M in 2024, whereas Other Liabilities is likely to drop slightly above 16.9 M in 2024.

Other Current Liab Total Current Liabilities Other Liab Accounts Payable

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Poseida Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Poseida Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Poseida Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Poseida Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Poseida Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Poseida Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Poseida Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.At this time, Poseida Therapeutics' Net Working Capital is fairly stable compared to the past year. Short Term Debt is likely to rise to about 8.1 M in 2024, whereas Other Liabilities is likely to drop slightly above 16.9 M in 2024.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	43.3M	53.9M	71.3M	74.9M
Other Current Liabilities	17.2M	20.2M	31.1M	32.6M

Total Current Liabilities Other Current Liab

Poseida Therapeutics balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding
Other Current Liab		0.94	0.67	0.9	-0.91	0.27	0.22	0.74	0.94	0.72	0.84	0.63	0.75	0.82	0.71	0.78	0.77	0.31	0.42	0.78	0.02	0.79	0.73	-0.79	0.95	0.77
Total Current Liabilities	0.94		0.77	0.81	-0.98	0.46	0.09	0.8	0.91	0.77	0.88	0.71	0.8	0.9	0.62	0.82	0.79	0.19	0.56	0.81	0.04	0.89	0.78	-0.78	0.98	0.87
Other Liab	0.67	0.77		0.61	-0.84	0.43	0.44	0.61	0.7	0.89	0.88	0.68	0.88	0.9	0.58	0.82	0.94	0.0	0.56	0.83	0.51	0.92	0.88	-0.36	0.81	0.66
Net Tangible Assets	0.9	0.81	0.61		-0.83	0.2	0.45	0.61	0.97	0.83	0.84	0.72	0.85	0.83	0.94	0.88	0.69	0.13	0.5	0.88	0.0	0.72	0.84	-0.53	0.87	0.66
Retained Earnings	-0.91	-0.98	-0.84	-0.83		-0.52	-0.19	-0.75	-0.93	-0.85	-0.93	-0.8	-0.88	-0.95	-0.7	-0.89	-0.82	-0.07	-0.65	-0.89	-0.12	-0.93	-0.86	0.68	-0.99	-0.86
Accounts Payable	0.27	0.46	0.43	0.2	-0.52		-0.11	0.05	0.36	0.4	0.4	0.79	0.43	0.46	0.19	0.51	0.17	-0.7	0.88	0.51	0.25	0.4	0.41	-0.18	0.39	0.43
Other Assets	0.22	0.09	0.44	0.45	-0.19	-0.11		-0.17	0.3	0.57	0.28	0.3	0.55	0.31	0.58	0.48	0.46	-0.12	0.25	0.5	0.67	0.18	0.58	0.08	0.21	-0.18
Net Receivables	0.74	0.8	0.61	0.61	-0.75	0.05	-0.17		0.7	0.56	0.79	0.33	0.56	0.76	0.45	0.55	0.7	0.53	0.1	0.53	-0.3	0.84	0.54	-0.55	0.79	0.88
Other Stockholder Equity	0.94	0.91	0.7	0.97	-0.93	0.36	0.3	0.7		0.85	0.91	0.78	0.87	0.91	0.88	0.91	0.73	0.1	0.59	0.91	0.01	0.83	0.86	-0.6	0.95	0.79
Total Current Assets	0.72	0.77	0.89	0.83	-0.85	0.4	0.57	0.56	0.85		0.91	0.82	1.0	0.94	0.86	0.97	0.81	-0.13	0.69	0.98	0.34	0.87	1.0	-0.3	0.84	0.63
Common Stock	0.84	0.88	0.88	0.84	-0.93	0.4	0.28	0.79	0.91	0.91		0.79	0.91	0.99	0.8	0.93	0.86	0.06	0.57	0.92	0.1	0.96	0.9	-0.42	0.92	0.88
Property Plant Equipment	0.63	0.71	0.68	0.72	-0.8	0.79	0.3	0.33	0.78	0.82	0.79		0.83	0.82	0.75	0.91	0.52	-0.51	0.93	0.91	0.21	0.69	0.82	-0.25	0.72	0.65
Total Assets	0.75	0.8	0.88	0.85	-0.88	0.43	0.55	0.56	0.87	1.0	0.91	0.83		0.95	0.86	0.98	0.81	-0.12	0.71	0.98	0.34	0.87	1.0	-0.34	0.86	0.64
Short Long Term Debt Total	0.82	0.9	0.9	0.83	-0.95	0.46	0.31	0.76	0.91	0.94	0.99	0.82	0.95		0.79	0.95	0.85	0.0	0.64	0.94	0.16	0.97	0.94	-0.43	0.93	0.84
Total Stockholder Equity	0.71	0.62	0.58	0.94	-0.7	0.19	0.58	0.45	0.88	0.86	0.8	0.75	0.86	0.79		0.9	0.59	-0.08	0.56	0.9	0.07	0.64	0.85	-0.21	0.73	0.53
Property Plant And Equipment Net	0.78	0.82	0.82	0.88	-0.89	0.51	0.48	0.55	0.91	0.97	0.93	0.91	0.98	0.95	0.9		0.75	-0.2	0.77	1.0	0.24	0.85	0.97	-0.35	0.87	0.7
Current Deferred Revenue	0.77	0.79	0.94	0.69	-0.82	0.17	0.46	0.7	0.73	0.81	0.86	0.52	0.81	0.85	0.59	0.75		0.31	0.31	0.75	0.39	0.89	0.81	-0.5	0.83	0.67
Net Debt	0.31	0.19	0.0	0.13	-0.07	-0.7	-0.12	0.53	0.1	-0.13	0.06	-0.51	-0.12	0.0	-0.08	-0.2	0.31		-0.69	-0.2	-0.28	0.14	-0.12	-0.49	0.2	0.16
Cash	0.42	0.56	0.56	0.5	-0.65	0.88	0.25	0.1	0.59	0.69	0.57	0.93	0.71	0.64	0.56	0.77	0.31	-0.69		0.77	0.33	0.51	0.7	-0.16	0.55	0.42
Non Current Assets Total	0.78	0.81	0.83	0.88	-0.89	0.51	0.5	0.53	0.91	0.98	0.92	0.91	0.98	0.94	0.9	1.0	0.75	-0.2	0.77		0.27	0.84	0.98	-0.35	0.87	0.68
Non Currrent Assets Other	0.02	0.04	0.51	0.0	-0.12	0.25	0.67	-0.3	0.01	0.34	0.1	0.21	0.34	0.16	0.07	0.24	0.39	-0.28	0.33	0.27		0.15	0.36	0.04	0.09	-0.27
Long Term Debt	0.79	0.89	0.92	0.72	-0.93	0.4	0.18	0.84	0.83	0.87	0.96	0.69	0.87	0.97	0.64	0.85	0.89	0.14	0.51	0.84	0.15		0.86	-0.47	0.92	0.87
Cash And Short Term Investments	0.73	0.78	0.88	0.84	-0.86	0.41	0.58	0.54	0.86	1.0	0.9	0.82	1.0	0.94	0.85	0.97	0.81	-0.12	0.7	0.98	0.36	0.86		-0.33	0.85	0.62
Good Will	-0.79	-0.78	-0.36	-0.53	0.68	-0.18	0.08	-0.55	-0.6	-0.3	-0.42	-0.25	-0.34	-0.43	-0.21	-0.35	-0.5	-0.49	-0.16	-0.35	0.04	-0.47	-0.33		-0.72	-0.52
Common Stock Total Equity	0.95	0.98	0.81	0.87	-0.99	0.39	0.21	0.79	0.95	0.84	0.92	0.72	0.86	0.93	0.73	0.87	0.83	0.2	0.55	0.87	0.09	0.92	0.85	-0.72		0.84
Common Stock Shares Outstanding	0.77	0.87	0.66	0.66	-0.86	0.43	-0.18	0.88	0.79	0.63	0.88	0.65	0.64	0.84	0.53	0.7	0.67	0.16	0.42	0.68	-0.27	0.87	0.62	-0.52	0.84

Click cells to compare fundamentals

Poseida Therapeutics Account Relationship Matchups

Poseida Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	1.7M	19.6M	17.2M	20.2M	31.1M	32.6M
Total Current Liabilities	21.9M	30.0M	43.3M	53.9M	71.3M	74.9M
Other Liab	22.6M	25.0M	14.9M	27.5M	31.6M	16.9M
Net Tangible Assets	(155.1M)	256.4M	150.7M	182.0M	209.4M	219.8M
Retained Earnings	(152.2M)	(281.9M)	(406.9M)	(470.9M)	(594.3M)	(564.6M)
Accounts Payable	4.9M	763K	9.0M	2.2M	3.3M	3.5M
Other Assets	3.4M	28.6M	1.7M	1.1M	1.2M	1.2M
Other Stockholder Equity	(219.5M)	543.8M	563.1M	658.6M	697.9M	732.7M
Total Current Assets	127.2M	314.0M	213.9M	298.6M	226.5M	171.6M
Property Plant Equipment	10.9M	23.3M	48.2M	21.6M	24.8M	17.4M
Total Assets	147.0M	371.5M	269.3M	351.8M	273.9M	233.2M
Short Long Term Debt Total	29.1M	59.3M	61.2M	88.8M	85.4M	55.4M
Total Stockholder Equity	(149.5M)	262.0M	156.2M	187.6M	103.7M	70.7M
Property Plant And Equipment Net	10.9M	48.3M	48.2M	46.7M	40.8M	31.4M
Net Debt	(58.6M)	(24.7M)	(145.1M)	7.4M	41.0M	43.0M
Cash	87.8M	84.0M	206.3M	81.4M	44.5M	86.4M
Non Current Assets Total	19.8M	57.5M	55.4M	53.3M	47.4M	40.2M
Non Currrent Assets Other	3.4M	3.6M	1.7M	1.1M	1.1M	1.8M
Long Term Debt	26.1M	29.1M	29.4M	58.3M	58.6M	36.0M
Cash And Short Term Investments	125.3M	309.2M	206.3M	282.5M	212.2M	185.7M
Liabilities And Stockholders Equity	147.0M	371.5M	269.3M	351.8M	273.9M	233.2M
Non Current Liabilities Total	274.7M	79.5M	69.8M	110.4M	98.9M	90.7M
Other Current Assets	434K	4.8M	7.5M	7.0M	5.3M	4.0M
Total Liab	296.5M	109.5M	113.1M	164.2M	170.2M	162.5M
Net Invested Capital	(120.4M)	291.1M	185.6M	245.8M	162.3M	107.3M
Property Plant And Equipment Gross	10.9M	48.3M	57.4M	60.1M	59.6M	37.9M
Accumulated Other Comprehensive Income	19K	5K	0.0	(149K)	126K	132.3K
Non Current Liabilities Other	5.4M	50.3M	31.1M	30.7M	2.6M	2.5M
Net Working Capital	105.3M	284.0M	170.5M	244.7M	155.2M	155.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Poseida Historical Balance Sheet

About Poseida Balance Sheet Analysis

Poseida Therapeutics Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Poseida Therapeutics balance sheet Correlations

Poseida Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Poseida Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Poseida Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Short Long Term Debt Total	+ 0.99	Common Stock
Common Stock Total Equity	+ 0.98	Total Current Liabilities

Common Stock Total Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Short Long Term Debt Total	- 0.95	Retained Earnings
Long Term Debt	- 0.93	Retained Earnings
Common Stock	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.93	Retained Earnings